RXi Awarded NIGMS Grant to Improve Self-Delivering RNAi Agents | GenomeWeb

RXi Pharmaceuticals last month won a six-month grant from the National Institute of General Medical Sciences worth $273,824 to make improvements to its self-delivering RNAi technology.

With the funding, RXi plans to develop a panel of second-generation self-delivering RNAi molecules, called sd-rxRNAs, with “improved potency and pharmacology by incorporating modified nucleotide bases with lipophilic moieties,” according to the grant's abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.